首页 | 官方网站   微博 | 高级检索  
     

多发性骨髓瘤的新免疫治疗:程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)检查点阻断
引用本文:高 英,李静静,柴 晔.多发性骨髓瘤的新免疫治疗:程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)检查点阻断[J].现代肿瘤医学,2019,0(15):2788-2790.
作者姓名:高 英  李静静  柴 晔
作者单位:兰州大学第二医院血液科,甘肃 兰州 730030
基金项目:兰州大学第二医院院内基金(编号:sdkyjj-26)
摘    要:多发性骨髓瘤是一种B淋巴细胞克隆性恶性肿瘤,近十年来,骨髓瘤的治疗模式发生了重大的演变,对疾病发病机制的认识不断深入,研发了不仅靶向肿瘤细胞而且靶向其微环境的治疗剂,使得多发性骨髓瘤的疗效和患者生存显著改善,但复发或难治性骨髓瘤患者的预后仍然很差,需要开发新的治疗方法。PD-1/PD-L1阻断可恢复多发性骨髓瘤效应细胞介导的抗肿瘤免疫应答。靶向作用于PD-1/PD-L1轴的免疫检测点抑制剂已经成为能控制抗肿瘤免疫应答有希望的药物。本文对近年PD-1/PD-L1检查点阻断在多发性骨髓瘤治疗中的进展做一综述。

关 键 词:多发性骨髓瘤  PD-1/PD-L1  免疫治疗

New immunotherapy for multiple myeloma:Programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint block
Gao Ying,Li Jingjing,Chai Ye.New immunotherapy for multiple myeloma:Programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint block[J].Journal of Modern Oncology,2019,0(15):2788-2790.
Authors:Gao Ying  Li Jingjing  Chai Ye
Affiliation:Department of Hematology,Lanzhou University Second Hospital,Gansu Lanzhou 730030,China.
Abstract:Multiple myeloma is a clonal malignant tumor of B lymphocytes.In recent ten years,the treatment mode of myeloma has undergone significant changes,and the understanding of the pathogenesis of the disease has deepened.Developing a therapeutic agent that targets not only tumor cells but also its microenvironment,which makes the curative effect of multiple myeloma and the survival of the patient significantly improved,but the prognosis of patients with recurrent or refractory myeloma is still poor and needs to be developed.PD-1/PD-L1 blockade restores multiple myeloma effector cell-mediated anti-tumor immune responses.Inhibitors targeting the PD-1/PD-L1 axis have become promising drugs that can control anti-tumor immune responses.This review summarizes recent advances in PD-1/PD-L1 checkpoint blocking in the treatment of multiple myeloma.
Keywords:multiple myeloma  PD-1/PD-L1  immunotherapy
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号